An Airport Spa And Biosecurity Co. Act As "Surveillance" In US Airports As Part Of $60M CDC "Early Warning" Contract For SARS-CoV-2
Ginkgo Bioworks Holdings Inc (NYSE: DNA) and XpresSpa Group Inc (NASDAQ: XSPA) have secured a new contract to continue to support the Centers for Disease Control and Prevention's (CDC's) traveler-based SARS-CoV-2 genomic surveillance program.
The partnership is expected to support public health and biosecurity services totaling ~$16 million, with an overall potential to exceed $61 million based on CDC program options and public health priorities.
The partners intend to broaden the program's scope and add cutting-edge modalities and offerings, such as the monitoring of wastewater from aircraft lavatories, as COVID-19 sublineages and other biological threats continue to emerge.
The parties have partnered since August 2021 to deliver timely public health data. The program is slated to expand its footprint with additional testing sites.
The expanded program will serve as an early warning system to detect new or emerging variants and can facilitate response to future travel-associated outbreaks and pandemics.
Price Action: DNA shares are trading lower by 3.03% at $3.52 and XSPA lower by 5.51% at $0.88 on the last check Monday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
Ā© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
